From: Drug-related problems reported by patients with rheumatic diseases: an observational study
Sex (male), n (%) | 27 (52%) |
Age (years), median (IQR) | 68 (62–74) |
Diagnosis, number of patients (%) | |
Rheumatoid arthritis | 34 (65%) |
Psoriatic arthritis | 7 (13%) |
Spondyloarthritis | 3 (6%) |
Polymyalgia rheumatica | 3 (6%) |
Gout | 3 (6%) |
Osteoarthritis | 2 (4%) |
Osteoporosis | 1 (2%) |
Polyarthritis | 1 (2%) |
Sjogren’s syndrome | 1 (2%) |
Temporal arteritis | 1 (2%) |
Disease duration (years), median (IQR) | 10 (5–20) |
Medication categories prescribed by rheumatologist, number of patients (%) | |
DMARDs | |
csDMARDs | 34 (65%) |
bDMARDs | 32 (62%) |
Analgesics | |
NSAIDs | 28 (54%) |
Paracetamol | 26 (50%) |
Corticosteroids | 16 (31%) |
Opioids | 4 (8%) |
Other | |
Gastric acid-reducing drugs | 31 (60%) |
Folic acid | 27 (52%) |
Osteoporosis medication | 20 (38%) |
Laxatives | 7 (13%) |
Artificial tears | 7 (13%) |
Antigout preparations | 2 (4%) |
Raynaud’s syndrome medication | 2 (4%) |
Antiemetics | 1 (2%) |